Journal Article (Review Article)

DKFZ-2017-06215

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png [Personalized oncology].

Heining, C. (First author)DKFZ* ; Horak, P.DKFZ* ; Gröschel, S.DKFZ* ; Glimm, H.DKFZ* ; Fröhling, S. (Last author)DKFZ*

2017
Springer Berlin

This record in other databases:  

Please use a persistent id in citations: doi:10.1007/s00117-017-0297-9

Abstract: Innovative next generation sequencing (NGS) technologies and comprehensive sequencing investigations in large patient cohorts have paved the way for very promising personalized treatment strategies based on the molecular characteristics of individual tumors.Targeted therapies, such as tyrosine kinase inhibitors, antibodies and modern immunotherapeutic approaches are well established as monotherapy and combination therapy for many hematological and oncological malignancies.A plethora of innovative therapies targeting various components of intracellular signaling cascades and effective mechanisms against oncogenes as well as the availability of NGS technologies enable personalized cancer treatment based on the molecular profiles of individual tumors and genetic stratification, within clinical trials.Comprehensive genetic approaches including cancer gene panel sequencing, whole exome, whole genome and transcriptome sequencing are carried out to a varying extent and particularly in the academic setting.Principally, a comprehensive characterization of tumors in addition to DNA and RNA sequencing that also incorporates epigenetic, metabolomic, and proteomic alterations would be desirable. A comprehensive clinical implementation of integrative, multidimensional genetic typing is, however, currently not possible.It remains to be demonstrated whether these approaches will translate into significantly better outcomes for patients and whether they can be increasingly implemented in the routine diagnostic work-up.The selection of diagnostic tools in individual cases and the extent of genomic analyses in the clinical context, need to take the availability of methods as well as the present clinical situation into account.

---

Contributing Institute(s):

1. Translationale Onkologie (G100)
2. Molekulare Leukämogenese (G240)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2017

---

Database coverage:
; Current Contents - Clinical Medicine ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---